Business Wire

BEHAVOX

18.5.2022 15:51:04 CEST | Business Wire | Pressemeddelelse

Del
Behavox-forskning i kontinuerlig læring med på International Conference on Acoustics, Speech and Signal Processing (ICASSP)

Behavox , som udbyder en række sikkerhedsprodukter, der hjælper compliance-, HR- og sikkerhedsafdelingerne med at beskytte deres virksomhed og kolleger mod ondsindede aktører, fortæller i dag, at dens akademiske forskningsdokument om kunstig intelligens "kontinuerlig læring med lattice-fri MMI til stemmegenkendelse" er blevet accepteret af International Conference on Acoustics, Speech, and Signal Processing (ICASSP). ICASSP er verdens største og mest omfattende tekniske konference med fokus på signalbehandling og tilhørende anvendelse. Behavox præsenterede den 9. maj 2022 dette dokument i Singapore for IEEE ICASSP 2022 .

"Nogle gange forsker videnskabsfolk for videnskabens skyld, og samfundet oplever ikke nogen umiddelbare fordele af forskningen. Vi har derimod skubbet videnskaben til en ny grænse for at finde en løsning på et aktuelt problem," siger Behavox's CTO Joseph Benjamin. "Vi er beærede over at have modtaget anerkendelse fra en så prestigefyldt konference og er meget stolte af vores team og det arbejde, folkene har udført."

Dokumentet, der er forfattet af Behavox's maskinlæringsteam, ser på udfordringerne i forbindelse med løbende forbedring af stemmegenkendelsessystemer i miljøer, der kræver beskyttelse af personoplysninger. Vores forskning har direkte forbindelse til Behavox's FoU-tilgang, der giver kunderne den bedste transskriptionskvalitet på det finansielle marked. I FinTech sker der hele tiden ændringer i det sprog og de data, som Behavox-systemerne hurtigt og pålideligt skal behandle, og stigningen i kryptovalutaer og videokommunikation er blot to eksempler.

Derfor skal maskinlæringsmodeller jævnligt opdateres med relevante data. For at gøre sådanne opdateringer mulige, uden at sætte databeskyttelsen over styr, skal modellen gradvist kunne forbedres i sikre klientmiljøer uden adgang til historiske data og data fra andre kunder. Dette er en alvorlig udfordring inden for maskinlæring på grund af den katastrofale glemsomhed, hvor modellen, efter at have forbedret en bestemt type data, begynder at præstere dårligt på tidligere lærte data.

ICASSP-dokumentet fra Behavox bidrager til den fortsatte læring til brug ved stemmegenkendelse. Forfatterne foreslår en ny algoritme, der udvider og forfiner den almindeligt anvendte LWF-teknik (Learning Without Forgetting), der er afhængig af en regulariseringsterm og tvinger neurale netværk til at mindske glemsomhed. Mere specifikt designede forfatterne en nyhed i form af neurale netværk med indlæring af tab på sekvensniveau, der kan bruges i stedet for den konventionelle, punktvise LWF. De viste en betydelig reduktion i glemsomhed, når man finjusterede det neurale netværk sekventielt efter forskellige accenter- og taleformer.

Behavox har konstateret, at brugen af stemmeplatforme med årene er steget 94 procent, og at næsten en tredjedel af al kommunikation på arbejdspladsen i gennemsnit foregår som telefonmøder eller videokonferencer.

Denne teknik er allerede blevet anvendt med succes på dets danske system, hvor samarbejdet mellem Behavox's lingvister, maskinlæringsteamet og en kunde gav Behavox mulighed for at opbygge sit første danske transskriptionssystem, der arbejder pålideligt med bankdata.

Om Behavox

Behovox udbyder en række sikkerhedsprodukter, der hjælper compliance-, HR- og sikkerhedsafdelingerne med at beskytte deres virksomhed og kolleger mod ondsindede aktører.

Med AI-baseret analyse af alle virksomhedens kommunikationsdata, herunder e-mail, chat, telefonmøde- og videokonferenceplatforme, hjælper Behavox virksomhederne med at identificere ulovlig, umoralsk og skadelig adfærd på arbejdspladsen.

Behavox, der blev grundlagt i 2014, har hovedkvarter i Montreal og kontorer i New York, London, Seattle, Singapore og Tokyo.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye